The following policy may be found in *ACPE Continuing Pharmacy Education Provider Accreditation Program Policies and Procedures Manual: A Guide for ACPE-accredited Providers*

Policy 14.0 Extended-Release (ER) and Long-Acting (LA) opioid analgesics Risk Evaluation and Mitigation Strategy (REMS)

The FDA required REMS program is a strategy set in place to assist in ensuring that the benefits of ER/LA opioid analgesics outweigh the risks before being prescribed to patients. It is strongly encouraged for all prescribers (physicians, nurse practitioners, physician assistants, and dentists) and other health care providers with direct patient care (pharmacists). The goal of REMS-compliant programs is to combat the current prescription drug abuse epidemic. This will be done by ensuring that REMS-compliant activities meet the following accreditation requirements:

- All activities must be delivered by an accredited continuing education (CE) provider
- Will incorporate all aspects of the FDA blueprint
- Will include a post-course knowledge assessment
- Are subject to independent audit of content and compliance with applicable accrediting standards

Procedure 14.0

1. All components of the FDA approved blueprint must be incorporated into the accredited CE activities.
2. Manufacturers of the ER/LA opioid analgesics, known as REMS Program Companies (RPC), support funding for all REMS-compliant CE activities.
3. The activities should meet the above requirements, contain keywords ER/LA opioid REMS and be entered into the Provider Web Tool. Under the General Activity Information tab, select 'yes' REMS to be distinguished from other CPE activities.
4. All RPC-supported REMS-compliant training activities from accredited CE providers will be made available and listed on the REMS website
5. Monitoring: Accredited providers who offer ER/LA opioid analgesics REMS training will be asked to demonstrate compliance with ACPE Accreditation Standards for Continuing Pharmacy Education and Policies by being subject to independent audit.